The U.S. FDA approvals by modality in 2019: first approval for a #nanobody and burst of #AntibodyDrugConjugate Nature Reviews Drug Discovery go.nature.com/2tQH4wF

Congratulations to ⁦Daiichi Sankyo US⁩ on a second interesting #antibodydrugconjugate candidate and collaboration with ⁦AstraZenecaUS⁩. Yet another clear sign of renewed and growing interest and excitement for new platforms and next-gen #ADCs wsj.com/articles/astra…

Near-infrared #photoimmunotherapy - which uses near infrared light to locally unleash the toxicity of an #AntibodyDrugConjugate - shows positive results in phase 2A #ClinicalTrial in #HNSCC #cancer patients: ORR=43%. #HisatakaKobayashi et al. Bioconjugate Chem bit.ly/2lVCglu

Thrilled to share my latest paper in Bioconjugate Chem on the impact of an unexpected #thiol state on the #stability of a novel #antibodydrugconjugate scaffold. Thank you to all the Cambridge Chemistry and AstraZeneca collaborators for this great teamwork!

#VIIIEWDSy next edition will be held on Maya 2020 at #CertosaPontignano more info about #EWDSy on ewdsy.com #medicinalchemistry #synthesis #greenchemistry #antibodydrugconjugate #anticancer #biocatalysis #sci … instagram.com/p/B5FggmXngLZ/…

The U.S. FDA has accepted our Biologics License Application with Priority Review designation for tisotumab vedotin, an investigational #AntibodyDrugConjugate being co-developed with Seagen, intended to treat women with recurrent or metastatic #CervicalCancer .

Read a new publication in Molecular Cancer Therapeutics that details the discovery and preclinical characterization of a novel #AntibodyDrugConjugate that is now being investigated in a Phase 1 #ClinicalTrial . #ADC aacrjournals.org/mct/article/do…

FDA grants accelerated approval to enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial carcinoma | FDA fda.gov/drugs/resource…

Alterations in both TROP2 (the antibody target) and TOP1 (the payload target) were identified in patients with acquired resistance to sacituzumab govitecan 🤯🤯🤯 #antibodydrugconjugate #bcsm

See QSC #FlowCytometry #microspheres at work for the #quantitation of #EGFR in the development of an #AntibodyDrugConjugate #ADC Cambridge Healthtech Institute #AntibodyDiscovery forum #Cancer #immunotherapy AbbVie bit.ly/BLIquant bit.ly/ABBV_EGFR

Attending #17ICML ? Don't miss Paolo F. Caimi's presentation of updated results from our LOTIS-2 pivotal Phase 2 clinical trial evaluating our CD19-targeted #antibodydrugconjugate . More details here: bit.ly/3qv6T2h

Exciting news! The #AntibodyDrugConjugate enfortumab vedotin-ejfv in combo with #immunotherapy pembro has been FDA-approved for cisplatin-ineligible advanced #BladderCancer patients. 🦠🔬 Could this targeted approach eventually replace cisplatin treatment altogether? #ADC

Purcell: Ph1 data on PTK7 #antibodydrugconjugate ABBV-647 PF-06647020 shows good safety profile and activity in #OvCa #NSCLC #TNBC . (On a personal note, I'm happy to hear from this 'old friend'!) #FOBUSA

Antibody-drug conjugates are one of the backbones of #nanomedicine . In a collaboration between Cambridge Chemistry and AstraZeneca, Carolina Orozco et al. explores the unexpected way a new thiol impacts the isolated antibody via disulfide bond formation.

pubs.acs.org/doi/10.1021/ac…

*Attention Advisors* The headlines about market volatility and recession are hard to ignore. Watch “5 High-Value Retirement Tax Planning Conversations” with Ed Slott on-demand now.

For an antibody drug conjugate to be effective, it’s essential to choose the right antibody. Two of the most popular options are IgG1 and IgG4. Here are key factors to consider when selecting your mAb. #mAb #ADC #antibodydrugconjugate lgmpharma.com/blog/how-the-r…

We are pleased to announce, along with our partner Swedish Orphan Biovitrum (Sobi), the European Commission has granted conditional marketing authorization for the use of our CD19-targeted #antibodydrugconjugate . $ADCT bit.ly/3WfUESe

#WorldADC kicks off today! With more than 650 attendees and 91 expert speakers, it’s the premier scientific ADC conference of the year. Let’s connect to maximize the clinical therapeutic window of your ADC
World ADC Beacon #antibodydrugconjugate #conference

XMT-2056 is now in the clinic! Learn about our Phase 1 clinical trial of this #Immunosynthen #AntibodyDrugConjugate here: ir.mersana.com/news-releases/…

#AntibodyDrugConjugate #TrastuzumabDeruxtecan ( #TDXd ) produces a durable response in more than half of patients with #NonSmallCellLungCancer ( #NSCLC ) harboring a #HER2mutation .
#LungCancer #LungCancer Treatment #ESMO21 bitly.com/3nKBipT

Register now for the 2023 NSC Safety Congress & Expo, October 20-26 in New Orleans. The world's largest industry-leading technology, education, and networking opportunities. More than 700 exhibitors showcasing the latest safety solutions & more than 125 Educational Opportunities.

Please read our latest open access article on targeting #CLDN6 by an #antibodydrugconjugate in #testiscancer and how we deciphered #therapy #resistance in yolk-sac tumors to identify new therapeutic approaches

BMC
Uniklinik Düsseldorf
DGU

molmed.biomedcentral.com/articles/10.11…

Today at #ASH22 , we present exciting preclinical data on VIP943, our novel anti-CD123 #antibodydrugconjugate , in AML.
Read our press release here: ow.ly/nRzR50M0oY8

Pharmaceuticals Highly Cited Papers by Dr. Nicolas Joubert et al.: #Antibody –Drug Conjugates: The Last Decade.

#Antibody DrugConjugate #Bioconjugation #Cancer #CombinationTherapies

📄View Full-Text Via:
mdpi.com/1424-8247/13/9…